Cardiovascular and Renal Effectiveness of GLP-1 Receptor Agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Studies
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Cardiovascular outcome trials (CVOT) showed that treatment with glucagon-like peptide-1 receptor agonists (GLP-1RA) is associated with significant cardiovascular benefits. However, CVOT are scarcely representative of everyday clinical practice, and real-world studies could provide clinicians with more relatable evidence. Here, literature was thoroughly searched to retrieve real-world studies investigating the cardiovascular and renal outcomes of GLP-1RA vs. other glucose-lowering drugs and carry out relevant meta-analyses thereof. Most real-world studies were conducted in populations at low cardiovascular and renal risk. Of note, real-world studies investigating cardio-renal outcomes of GLP-1RA suggested that initiation of GLP-1RA was associated with a greater benefit on composite cardiovascular outcomes, MACE (major adverse cardiovascular events), all-cause mortality, myocardial infarction, stroke, cardiovascular death, peripheral artery disease, and heart failure compared to other glucose-lowering drugs with the exception of sodium-glucose transporter-2 inhibitors (SGLT-2i). Initiation of SGLT-2i and GLP-1RA yielded similar effects on composite cardiovascular outcomes, MACE, stroke, and myocardial infarction. Conversely, GLP-1RA were less effective on heart failure prevention compared to SGLT-2i. Finally, the few real-world studies addressing renal outcomes suggested a significant benefit of GLP-1RA on estimated glomerular filtration rate (eGFR) reduction and hard renal outcomes vs. active comparators except SGLT-2i. Further real-world evidence is needed to clarify the role of GLP-1RA in cardio-renal protection among available glucose-lowering drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900 · cited 1×
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
BackgroundSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 3×
“87) [16], yet these results were mainly driven by prevention of macroalbuminuria, whereas data on hard kidney endpoints were inconclusive due to the low number of events accrued [38].”
BackgroundResultCardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514 · cited 1×
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
BackgroundSGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Verma, S., & McMurray, J. J. V. (2018) · Diabetologia · doi:10.1007/s00125-018-4670-7 · Cited by 999 · cited 1×
“Indeed, while SGLT-2i seemingly exert cardiovascular protection very early on after initial exposure [45], GLP-1RA likely require several months, especially in populations at low baseline cardiovascular risk [36]; thus, real-world studies might have been too short to detect the actual extent of GLP-1RA-mediated cardio…”
Background9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s009 · Cited by 972
Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes
Gerstein, H. C., Sattar, N., Rosenstock, J., Ramasundarahettige, C., Pratley, R., Lopes, R. D., Lam, C. S. P., Khurmi, N. S., Heenan, L., Del Prato, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108269 · Cited by 829 · cited 1×
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
BackgroundGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31150-x · Cited by 638
Ueda, P., Svanström, H., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2018) · BMJ · doi:10.1136/bmj.k4365 · Cited by 367 · cited 1×
“Accordingly, data from Swedish and Danish nationwide registries demonstrated that GLP-1RA users exhibited a significantly reduced risk of lower limb amputations compared to SGLT-2i [37].”
BackgroundBray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194
Carls, G. S., Tuttle, E., Tan, R.-D., Huynh, J., Yee, J., Edelman, S. V., & Polonsky, W. H. (2017) · Diabetes Care · doi:10.2337/dc16-2725 · Cited by 153 · cited 1×
“suggested that poor adherence could account for up to 75% of the gap that can be found between randomized controlled trials and real-world studies results [52].”
Dhatariya, K., Bain, S. C., Buse, J. B., Simpson, R., Tarnow, L., Kaltoft, M. S., Stellfeld, M., Tornøe, K., Pratley, R. E., & the LEADER Publication Committee on behalf of the LEADER Trial Investigators (2018) · Diabetes Care · doi:10.2337/dc18-1094 · Cited by 141
Rizzo, M., Rizvi, A. A., Patti, A. M., Nikolic, D., Giglio, R. V., Castellino, G., Li Volti, G., Caprio, M., Montalto, G., Provenzano, V., et al. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0480-8 · Cited by 135 · cited 2×
“2 mg/day to metformin was able to improve cardio-metabolic risk factors in 121 individuals with type 2 diabetes and metabolic syndrome after 18 months [10].”
BackgroundPatorno, E., Pawar, A., Bessette, L. G., Kim, D. H., Dave, C., Glynn, R. J., Munshi, M. N., Schneeweiss, S., Wexler, D. J., & Kim, S. C. (2021) · Diabetes Care · doi:10.2337/dc20-1464 · Cited by 121 · cited 4×
“76, I2 = 0%) (Figure 3D), both in patients with previous cardiovascular disease [30,31] and at low cardiovascular risk [31,33,35,36].”
BackgroundInfluentialO’Brien, M. J., Karam, S. L., Wallia, A., Kang, R. H., Cooper, A. J., Lancki, N., Moran, M. R., Liss, D. T., Prospect, T. A., & Ackermann, R. T. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.6125 · Cited by 113 · cited 4×
“The meta-analysis of five studies addressing the risk of heart failure-related outcomes as a secondary endpoint [17,19,21,22,25] showed an overall 12% reduction in initiators of GLP1RA vs.”
BackgroundMethodInfluentialPatorno, E., Htoo, P. T., Glynn, R. J., Schneeweiss, S., Wexler, D. J., Pawar, A., Bessette, L. G., Chin, K., Everett, B. M., & Kim, S. C. (2021) · Annals of Internal Medicine · doi:10.7326/m21-0893 · Cited by 103 · cited 4×
“76, I2 = 0%) (Figure 3D), both in patients with previous cardiovascular disease [30,31] and at low cardiovascular risk [31,33,35,36].”
BackgroundInfluentialLongato, E., Di Camillo, B., Sparacino, G., Gubian, L., Avogaro, A., & Fadini, G. P. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001451 · Cited by 83 · cited 5×
“76, I2 = 0%) (Figure 3D), both in patients with previous cardiovascular disease [30,31] and at low cardiovascular risk [31,33,35,36].”
BackgroundInfluentialNikolic, D., Giglio, R. V., Rizvi, A. A., Patti, A. M., Montalto, G., Maranta, F., Cianflone, D., Stoian, A. P., & Rizzo, M. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00962-3 · Cited by 81 · cited 2×
“further investigated this association, demonstrating that this treatment regimen led to lower carotid intima-media thickness through reduction in atherogenic small dense LDL concentrations in 62 type 2 diabetic patients followed for 4 months [11].”
BackgroundResultAnholm, C., Kumarathurai, P., Pedersen, L. R., Samkani, A., Walzem, R. L., Nielsen, O. W., Kristiansen, O. P., Fenger, M., Madsbad, S., Sajadieh, A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.07.007 · Cited by 75 · cited 1×
“Furthermore, in small placebo-controlled randomized controlled trials, the combination of metformin and liraglutide may reduce the levels of the most atherogenic LDL subfraction and C-reactive protein in patients with coronary artery disease and new onset type 2 diabetes [7].”
BackgroundSvanström, H., Ueda, P., Melbye, M., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., & Pasternak, B. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30320-6 · Cited by 71 · cited 2×
“The meta-analysis of five studies addressing the risk of heart failure-related outcomes as a secondary endpoint [17,19,21,22,25] showed an overall 12% reduction in initiators of GLP1RA vs.”
BackgroundMethodPasternak, B., Wintzell, V., Eliasson, B., Svensson, A.-M., Franzén, S., Gudbjörnsdottir, S., Hveem, K., Jonasson, C., Melbye, M., Svanström, H., et al. (2020) · Diabetes Care · doi:10.2337/dc19-2088 · Cited by 69
Giorgino, F., Penfornis, A., Pechtner, V., Gentilella, R., & Corcos, A. (2018) · Patient Preference and Adherence · doi:10.2147/ppa.s151736 · Cited by 68 · cited 1×
“While in randomized controlled trials patients’ adherence is actively supported, in everyday clinical practice approximately half of type 2 diabetic patients fail to reach their glycemic target, often due to lack of adherence to glucose-lowering drugs [51].”
Self-citationLin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · Diabetologia · doi:10.1007/s00125-021-05497-1 · Cited by 68 · cited 6×
“found that GLP-1RA administration was associated with a lower risk of myocardial infarction only when compared to DPP-4i [21,23], our meta-analysis of RWS showed a significant 10% myocardial infarction risk reduction with a low degree of heterogeneity (HR 0.”
BackgroundResultInfluentialLugner, M., Sattar, N. A., Miftaraj, M., Ekelund, J., Franzén, S., Svensson, A., & Eliasson, B. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01258-x · Cited by 62 · cited 3×
“035) [32] and lower limb amputations (HR 1.”
BackgroundResultInfluentialHeterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials
Caruso, I., Cignarelli, A., & Giorgino, F. (2019) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2019.07.004 · Cited by 58 · cited 1×
“, the unhandy device used for exenatide once weekly injection was likely the cause of the lowest exposure to the investigational product observed in the EXSCEL trial compared to other GLP-1RA) [50].”
ResultSelf-citationLongato, E., Di Camillo, B., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01049-w · Cited by 57 · cited 16×
“found that GLP-1RA administration was associated with a lower risk of myocardial infarction only when compared to DPP-4i [21,23], our meta-analysis of RWS showed a significant 10% myocardial infarction risk reduction with a low degree of heterogeneity (HR 0.”
MethodResultInfluentialUssher, J. R., Greenwell, A. A., Nguyen, M.-A., & Mulvihill, E. E. (2022) · Diabetes · doi:10.2337/dbi20-0049 · Cited by 50 · cited 1×
“, GLP-1RA-mediated cardiovascular protection could be mainly attributed to their vascular anti-inflammatory and anti-atherosclerotic actions, alongside improvements in heart glucose metabolism, fibrosis, oxidative stress, cardiomyocytes viability, and, even though to a small extent, in blood pressure [9].”
BackgroundYang, C.-T., Yang, C.-Y., Ou, H.-T., & Kuo, S. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01053-0 · Cited by 48
Baviera, M., Genovese, S., Lepore, V., Colacioppo, P., Robusto, F., Tettamanti, M., D'Ettorre, A., Avanzini, F., Fortino, I., Nicolucci, A., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14361 · Cited by 42 · cited 4×
“The meta-analysis of five studies addressing the risk of heart failure-related outcomes as a secondary endpoint [17,19,21,22,25] showed an overall 12% reduction in initiators of GLP1RA vs.”
BackgroundMethodResultInfluentialSelf-citationGuerci, B., Charbonnel, B., Gourdy, P., Hadjadj, S., Hanaire, H., Marre, M., & Vergès, B. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.01.006 · Cited by 40 · cited 2×
“, twice daily, once daily, once weekly) and the features of the delivery device seem to have a prominent impact on adherence rates [53].”
BackgroundBrixner, D. I., McAdam‐Marx, C., Ye, X., Boye, K. S., Nielsen, L. L., Wintle, M., Misurski, D., & Fabunmi, R. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01081.x · Cited by 38 · cited 1×
“Furthermore, in small cohort studies conducted in type 2 diabetic patients, liraglutide and exenatide exhibited benefits in line with those seen in RCT on glycemic control, body weight, blood pressure, total cholesterol and triglycerides levels, and other known cardiovascular risk factors over a follow-up period of 36…”
BackgroundPineda, E. D., Liao, I., Godley, P. J., Michel, J. B., & Rascati, K. L. (2020) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2020.26.5.610 · Cited by 35 · cited 3×
“found that GLP-1RA initiation significantly reduced the risk of the composite cardiovascular outcome by 29% [17], while Yang et al.”
BackgroundMethodJacob, S., Krentz, A. J., Deanfield, J. E., & Rydén, L. (2021) · Drugs · doi:10.1007/s40265-021-01554-6 · Cited by 34 · cited 1×
“The GLP-1RA- and SGLT-2i-mediated cardiovascular and renal protection that emerged from CVOT has recently led to a paradigm shift in diabetes care, urging clinicians to implement these new glucose-lowering drugs in patients at high cardio-renal risk, irrespective of glucose control [43].”
BackgroundNørgaard, C. H., Starkopf, L., Gerds, T. A., Vestergaard, P., Bonde, A. N., Fosbøl, E. L., Køber, L., Wong, N. D., Torp-Pedersen, C. T., & Lee, C. J.-Y. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab053 · Cited by 32
Patorno, E., Everett, B. M., Goldfine, A. B., Glynn, R. J., Liu, J., Gopalakrishnan, C., & Kim, S. C. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12665 · Cited by 31 · cited 4×
“failed to show any superiority of GLP-1RA over DPP-4i, sulphonylureas, and insulin, but the majority of GLP-1RA initiators were on exenatide bis in die [20].”
BackgroundInfluentialLiraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort
Mirani, M., Favacchio, G., Serone, E., Lucisano, G., Rossi, M. C., & Berra, C. C. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.003 · Cited by 31 · cited 1×
“Furthermore, in small cohort studies conducted in type 2 diabetic patients, liraglutide and exenatide exhibited benefits in line with those seen in RCT on glycemic control, body weight, blood pressure, total cholesterol and triglycerides levels, and other known cardiovascular risk factors over a follow-up period of 36…”
BackgroundSciannameo, V., Berchialla, P., Orsi, E., Lamacchia, O., Morano, S., Querci, F., Consoli, A., Avogaro, A., Fadini, G. P., & study, T. D. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13962 · Cited by 31
Toulis, K. A., Hanif, W., Saravanan, P., Willis, B. H., Marshall, T. P., Kumarendran, B., Gokhale, K. M., Ghosh, S., Cheng, K. K., Narendran, P., et al. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.02.003 · Cited by 30
Thomsen, R. W., Knudsen, J. S., Kahlert, J. A., Baggesen, L. M., Lajer, M., Holmgaard, P., Vedin, O., Ustyugova, A., & Sørensen, H. T. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019356 · Cited by 30 · cited 1×
“76, I2 = 0%) (Figure 3D), both in patients with previous cardiovascular disease [30,31] and at low cardiovascular risk [31,33,35,36].”
BackgroundAhmad, E., Waller, H. L., Sargeant, J. A., Webb, M. A., Htike, Z. Z., McCann, G. P., Gulsin, G., Khunti, K., Yates, T., Henson, J., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14343 · Cited by 27
Žerovnik, Š., Kos, M., & Locatelli, I. (2021) · BMJ Open · doi:10.1136/bmjopen-2021-051549 · Cited by 27
Giorgino, F., Caruso, I., Moellmann, J., & Lehrke, M. (2020) · Metabolism · doi:10.1016/j.metabol.2019.154045 · Cited by 26 · cited 3×
“Specifically, experimental studies suggested that liraglutide was able to hinder the progression of atherosclerosis and improve plaque stability [6].”
BackgroundInfluentialSelf-citationMorieri, M. L., Avogaro, A., & Fadini, G. P. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s216054 · Cited by 25 · cited 2×
“By including a broader population and allowing the accrual of a higher number of hard renal events [4], real-world studies yielded promising results on GLP-1RA-mediated renal protection, which complement those derived from the randomized controlled trials (Table 3).”
BackgroundResultDeRemer, C. E., Vouri, S. M., Guo, J. S., Donahoo, W. T., Winterstein, A. G., & Shao, H. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.107972 · Cited by 24 · cited 1×
“76, I2 = 0%) (Figure 3D), both in patients with previous cardiovascular disease [30,31] and at low cardiovascular risk [31,33,35,36].”
BackgroundBoye, K. S., Botros, F. T., Haupt, A., Woodward, B., & Lage, M. J. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0377-5 · Cited by 23 · cited 2×
“14%) with respect to other glucose-lowering drugs initiators [42].”
BackgroundLongato, E., Camillo, B. D., Sparacino, G., Tramontan, L., Avogaro, A., & Fadini, G. P. (2020) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa081 · Cited by 21 · cited 2×
“Indeed, excluding lixisenatide initiators, human-based GLP-1RA were still associated with a lower risk of MACE and hospitalization due to cardiovascular causes [49]; however, differences in patients’ adherence rates between groups were not addressed in this study [49] nor in other real-world studies investigating card…”
MethodResultRondinelli, M., Rossi, A., Gandolfi, A., Saponaro, F., Bucciarelli, L. G., Adda, G., Molinari, C., Montefusco, L. B., Specchia, C., Rossi, M. C., et al. (2016) · Clinical Therapeutics · doi:10.1016/j.clinthera.2016.11.001 · Cited by 20 · cited 1×
“6 mg/L and preserved eGFR at 36 months [40].”
BackgroundSeeger, J. D., Nunes, A., & Loughlin, A. M. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14021 · Cited by 20 · cited 3×
“However, the strict requirements of randomized controlled trials come at the expense of generalizability, as their results are reliably informative only for populations with the same features and in a similar setting of care [2].”
BackgroundWhy Choose Between SGLT2 Inhibitors and GLP1-RA When You Can Use Both? The Time to Act Is Now
CHENG, A. Y. Y. (2021) · Circulation · doi:10.1161/circulationaha.120.053058 · Cited by 18 · cited 1×
“Choosing between GLP-1RA or SGLT-2i might soon become obsolete, due to the mounting evidence supporting their additive beneficial CV effect [54].”
BackgroundAlkhezi, O. S., Alsuhaibani, H. A., Alhadyab, A. A., AlFaifi, M., Alomrani, B., Aldossary, A., & Alfayez, O. M. (2021) · Primary care diabetes · doi:10.1016/j.pcd.2021.04.005 · Cited by 14 · cited 16×
“Furthermore, real-world studies did not include patients on semaglutide [46], efpeglenatide [47], and ertugliflozin [48], which have been associated with significant cardiovascular protection and neutral cardiovascular effects, respectively, in recent dedicated CVOT.”
ResultInfluentialFrison, V., Simioni, N., Marangoni, A., Balzano, S., Vinci, C., Zenari, L., De Moliner, L., Tadiotto, F., D’Ambrosio, M., Confortin, L., et al. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0503-4 · Cited by 12
Precision medicine in diabetes and diabetic kidney disease: Regulatory considerations
Mol, P. G. M., Thompson, A., Heerspink, H. J. L., & Leufkens, H. G. M. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13453 · Cited by 11 · cited 2×
“The scientific community has been paying increasing attention to real-world studies, using data from electronic medical records, registries, health insurance claims, or surveys, which could provide clinicians with evidence closer to their everyday clinical practice in broader populations or usually underrepresented su…”
BackgroundCommentary: Glucose control: Not just a bystander in GLP-1RA-mediated cardiovascular protection
Caruso, I., Cignarelli, A., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154272 · Cited by 11 · cited 1×
“Mediation and meta-regression analyses of CVOT suggested that HbA1c reduction was a relevant mediator of the GLP-1RA beneficial effect on MACE, and this association seemed to be driven by that between HbA1c lowering and stroke [44].”
MethodSelf-citationCiresi, A., Vigneri, E., Radellini, S., Pantò, F., & Giordano, C. S. D. S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0338-4 · Cited by 7 · cited 1×
“Similarly, a small study conducted on 105 type 2 diabetic patients showed that adding liraglutide to metformin, but not to sulphonylureas, for at least 48 months was linked to a significant reduction in patients’ cardiovascular risk measured with the Framingham risk score [13].”
ResultBoye, K. S., Mody, R., Wu, J., Lage, M. J., Botros, F. T., & Woodward, B. (2018) · Clinical Therapeutics · doi:10.1016/j.clinthera.2018.07.002 · Cited by 7 · cited 1×
“Two real-world studies collecting data from the same US electronic health record database investigated to effect of GLP-1RA on eGFR compared to other glucose-lowering drugs in the first year after treatment initiation [41,42].”
Background
Cited by
Mancia, G., Kreutz, R., Brunström, M., Burnier, M., Grassi, G., Januszewicz, A., Muiesan, M. L., Tsioufis, K., Agabiti-Rosei, E., Algharably, E. A. E., et al. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003480 · Cited by 3,473
Overview of oxidative stress and inflammation in diabetes
Weinberg Sibony, R., Segev, O., Dor, S., & Raz, I. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.70014 · Cited by 292
Rivera, F. B., Cruz, L. L. A., Magalong, J. V., Ruyeras, J. M. M. J., Aparece, J. P., Bantayan, N. R. B., Lara-Breitinger, K., & Gulati, M. (2024) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2024.100679 · Cited by 155
Chinese Guidelines for the Prevention and Treatment of Hypertension (2024 revision)
Wang, J. (2025) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2025.01.008 · Cited by 196
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
“Cardiovascular outcome trials (CVOT) showed that treatment with GLP-1RA is associated with significant cardiovascular benefits [60].”
Background
Metadata
- Authors
- Caruso, I., Cignarelli, A., Sorice, G. P., Natalicchio, A., Perrini, S., Laviola, L., & Giorgino, F.
- Affiliations
- University of Bari Aldo Moro (IT)
- Corresponding author
- Giorgino, Francesco
- ORCID
- Venue
- Metabolites
- Publisher
- MDPI AG
- Published
- 2022-02-15
- Volume
- 12
- Issue
- 2
- Pages
- 183
- ISSN
- 2218-1989 (ISSN-L)
- PMC
- PMC8879165
- OpenAlex
- W4213149093
- Semantic Scholar
- 30aa3d4bd64a5d1daebd8eb1180f4cb1fa26274b
- Cited by
- 86
- References
- 54
- Citations by year
- 2026: 8 · 2025: 20 · 2024: 25 · 2023: 27 · 2022: 6
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Metabolites (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, cardiovascular outcomes, renal outcomes, sodium-glucose transporter 2 inhibitors, antidiabetic drugs, major adverse cardiovascular events, heart failure, estimated glomerular filtration rate, real-world evidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.